Literature DB >> 15720805

Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells.

Timo Faltus1, Juping Yuan, Brigitte Zimmer, Andrea Krämer, Sibylle Loibl, Manfred Kaufmann, Klaus Strebhardt.   

Abstract

In eukaryotes, double-stranded (ds) RNA induces sequence-specific inhibition of gene expression referred to as RNA interference (RNAi). We exploited RNAi to define the role of HER2/neu in the neoplastic proliferation of human breast cancer cells. We transfected SK-BR-3, BT-474, MCF-7, and MDA-MB-468 breast cancer cells with short interfering RNA (siRNA) targeted against human HER2/neu and analyzed the specific inhibition of HER2/neu expression by Northern and Western blots. Transfection with HER2/neu-specific siRNA resulted in a sequence-specific decrease in HER2/neu mRNA and protein levels. Moreover, transfection with HER2/neu siRNA caused cell cycle arrest at G0/G1 in the breast cancer cell lines SK-BR-3 and BT-474, consistent with a powerful RNA silencing effect. siRNA treatment resulted in an antiproliferative and apoptotic response in cells overexpressing HER2/neu, but had no influence in cells with almost no expression of HER2/neu proteins like MDA-MB-468 cells. These data indicate that HER2/neu function is essential for the proliferation of HER2/neu-overexpressing breast cancer cells. Our observations suggest that siRNA targeted against human HER2/neu may be valuable tools as antiproliferative agents that display activity against neoplastic cells at very low doses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15720805      PMCID: PMC1531682          DOI: 10.1593/neo.04313

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  44 in total

1.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.

Authors:  A Berchuck; G Rodriguez; R B Kinney; J T Soper; R K Dodge; D L Clarke-Pearson; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1991-01       Impact factor: 8.661

2.  Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides.

Authors:  J Bertram; M Killian; W Brysch; K H Schlingensiepen; M Kneba
Journal:  Biochem Biophys Res Commun       Date:  1994-04-15       Impact factor: 3.575

3.  Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.

Authors:  I Stancovski; E Hurwitz; O Leitner; A Ullrich; Y Yarden; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

4.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

Review 5.  The significance of oncogene amplification in primary breast cancer.

Authors:  R Seshadri; C Matthews; A Dobrovic; D J Horsfall
Journal:  Int J Cancer       Date:  1989-02-15       Impact factor: 7.396

6.  HER-2/neu oncogene protein and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; A Ullrich; W L McGuire
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

7.  Humanization of an anti-p185HER2 antibody for human cancer therapy.

Authors:  P Carter; L Presta; C M Gorman; J B Ridgway; D Henner; W L Wong; A M Rowland; C Kotts; M E Carver; H M Shepard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

8.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.

Authors:  C C Benz; G K Scott; J C Sarup; R M Johnson; D Tripathy; E Coronado; H M Shepard; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

9.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

10.  erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.

Authors:  R Colomer; R Lupu; S S Bacus; E P Gelmann
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more
  40 in total

1.  Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.

Authors:  Jonathan W Uhr; Michael L Huebschman; Eugene P Frenkel; Nancy L Lane; Raheela Ashfaq; Huaying Liu; Dipen R Rana; Lawrence Cheng; Alice T Lin; Gareth A Hughes; Xiaojing J Zhang; Harold R Garner
Journal:  Transl Res       Date:  2011-09-03       Impact factor: 7.012

2.  Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Swetlana Rot; Jacqueline Kessler; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-08-27       Impact factor: 3.621

Review 3.  Oligonucleotide-based theranostic nanoparticles in cancer therapy.

Authors:  Reza Shahbazi; Bulent Ozpolat; Kezban Ulubayram
Journal:  Nanomedicine (Lond)       Date:  2016-04-22       Impact factor: 5.307

Review 4.  Perspectives of HER2-targeting in gastric and esophageal cancer.

Authors:  James N Gerson; Sam Skariah; Crystal S Denlinger; Igor Astsaturov
Journal:  Expert Opin Investig Drugs       Date:  2017-05       Impact factor: 6.206

5.  Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients.

Authors:  Li Ding; Zijin Zhang; Yan Xu; Yongqiang Zhang
Journal:  Bioengineered       Date:  2017-01-11       Impact factor: 3.269

6.  Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line.

Authors:  Akihiro Naito; Jaime Carcel-Trullols; Cheng-hui Xie; Teresa T Evans; Takatsugu Mizumachi; Masahiro Higuchi
Journal:  Int J Cancer       Date:  2008-04-01       Impact factor: 7.396

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein.

Authors:  Sivakumar Jeyarajan; Jennifer Xavier; N Madhusudhana Rao; Vijaya Gopal
Journal:  Int J Nanomedicine       Date:  2010-10-05

Review 9.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

10.  Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies.

Authors:  Woo-Ram Lee; Ji-Young Jang; Jeong-Sun Kim; Myung-Hee Kwon; Yong-Sung Kim
Journal:  Nucleic Acids Res       Date:  2009-12-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.